Fundraising Fox
/Companies
Sign in

Omeicos Therapeutics

Berlin, DE · Founded 2013 · 9 employees on LinkedIn · 3 known investors

Find your way into Omeicos Therapeutics

Sign up to see every warm intro you have to Omeicos Therapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Omeicos Therapeutics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

OMEICOS is a biotech company developing small-molecule therapeutics based on synthetic analogues of omega-3 fatty acid derived epoxyeicosanoids (17,18-EEQ) for cardiovascular, inflammatory, and rare mitochondrial diseases. Its lead candidate OMT-28 is in Phase 2 clinical trials for conditions including atrial fibrillation and primary mitochondrial disease; the company was spun out of the Max Delbrück Center for Molecular Medicine in Berlin.

BiotechHealthtech

Founders & leadership

Omeicos Therapeutics was founded in 2013 by Robert Fischer, Karen Uhlmann, Wolf-Hagen Schunck, and John R. Falck.

RF
Robert FischerCEO/CSO & Co-FounderRobert Fischer is CEO and Chief Scientific Officer of Omeicos Therapeutics, a biotech company developing small-molecule therapeutics for cardiovascular and mitochondrial diseases. He has expertise in cardiology and cardiac arrhythmias, holds board certification in internal medicine, and has authored over 20 publications and contributed to 2 patents.
KUKaren Uhlmann
Karen UhlmannVice President Operations & IP, Co-FounderKaren Uhlmann is Vice President of Operations & IP and Co-Founder of Omeicos Therapeutics, a biotech company developing small-molecule therapeutics for cardiovascular, inflammatory, and rare mitochondrial diseases. She has experience in technology transfer and serves as an expert advisor for research funding and startup evaluation bodies in Europe.
WS
Wolf-Hagen SchunckCo-Founder
JR
John R. FalckCo-Founder

Investors · 3

Forbion✓ confirmed by Omeicos TherapeuticsNaarden

How we know: the company's own site · a partner's Signal profile · funding news · open dataset · 5k.vc investor directory · Not right? Tell us

Vesalius Biocapital Partnerslisted by Vesalius Biocapital PartnersLuxembourg · $11M

How we know: open dataset · 5k.vc investor directory · Not right? Tell us

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

Frequently asked questions

What does Omeicos Therapeutics do?
OMEICOS is a biotech company developing small-molecule therapeutics based on synthetic analogues of omega-3 fatty acid derived epoxyeicosanoids (17,18-EEQ) for cardiovascular, inflammatory, and rare mitochondrial diseases. Its lead candidate OMT-28 is in Phase 2 clinical trials for conditions including atrial fibrillation and primary mitochondrial disease; the company was spun out of the Max Delbrück Center for Molecular Medicine in Berlin.
Who founded Omeicos Therapeutics?
Omeicos Therapeutics was founded by Robert Fischer, Karen Uhlmann, Wolf-Hagen Schunck, John R. Falck in 2013.
Who are Omeicos Therapeutics's investors?
Omeicos Therapeutics's investors include Remiges Ventures, Inc., Forbion, Vesalius Biocapital Partners.
Where is Omeicos Therapeutics headquartered?
Omeicos Therapeutics is headquartered in Berlin, DE.